Ob/Gyn | Head of Cosmetic Gynecology @ IASO Hospital. Championing women’s health from adolescence to menopause. | HRT | Longevity & Preventive Health Advocate
Honoured to have participated in this year’s Delphi Economic Forum to discuss a subject close to my heart: The Quest for Longevity.
🎥 To view the video, I’ve prepared a highlight reel from the panel — don’t miss it! 💎 👉 https://t.co/Tze4SKCJZi
Your blood may carry a warning about lung cancer five years before a scan ever finds it.
Researchers read the plasma of 48,000 people and found a 14-protein pattern that’s already lit up more than five years before diagnosis. Not a tumor yet. A signal that one is coming.
The part that turns this from a test into a plan: when they looked back at people who carried the high-risk pattern, an existing anti-inflammatory drug cut their lung-cancer risk by about half.
Predict it early, then act on it.
How Fast Are You Aging? New Genetic Clock May Have the Answer 🕰️
A huge analysis of gene expression across species revealed genetic hallmarks of aging and could accelerate anti-aging treatments.
https://t.co/etTl2gaVdK
Ozempic activates a 'repair mode' in cartilage cells, boosting joint thickness by 17% and potentially reducing the need for invasive surgeries.
For years, experts assumed that the joint pain relief seen with Ozempic was mainly due to weight loss. A landmark 2026 study has challenged that view. Researchers from the Shenzhen Institutes of Advanced Technology discovered that semaglutide—the active ingredient in Ozempic—acts directly on cartilage cells (chondrocytes) to promote regeneration.
By reprogramming the cells' energy metabolism (shifting from inefficient glycolysis toward more efficient oxidative phosphorylation via the GLP-1R-AMPK-PFKFB3 pathway), the drug helps trigger a restorative process that rebuilds the protective cartilage cushioning in joints—tissue long thought to be irreplaceable once lost.
The results are striking. In a small pilot clinical study, advanced MRI scans showed an average 17% increase in cartilage thickness after six months of treatment, along with signs of new cartilage growth in weight-bearing areas. Patients also experienced reduced pain and improved joint function.
This breakthrough points to a new way of treating osteoarthritis: not just managing symptoms, but addressing the underlying structural damage. While larger trials are still needed, semaglutide is emerging as a promising option that could help millions of people avoid or delay joint replacement surgeries and restore mobility through direct cellular repair—independent of its well-known weight-loss effects.
[Qin, H., Yu, J., Yu, H., et al. (2026). Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism. Cell Metabolism, 38(3), 582–597.e6. DOI: 10.1016/j.cmet.2026.01.008]
INSTEAD OF WATCHING AN HOUR OF NETFLIX TONIGHT.
This 1 hour Stanford lecture by Joel Peterson will teach you more about negotiation and getting what you want than most people learn in years.
Bookmark it and give it an hour, no matter what.
Mitochondria in our cells have their own genome. A new paper @nature shows it mutates sharply after age 60. Now rare, one day it might be common to receive a mito-transplant later in life 🧬 https://t.co/pEbhh9SWY2
For 63 years, medicine couldn’t lower lipoprotein(a). Now everyone is trying at once.
Three Phase 3 trials. Over 32,000 patients. 35+ countries. Drugs hitting 80 to 94% Lp(a) reduction. The first results from 8,323 patients land this summer.
But that’s the injectable chapter. Behind it:
-> @EliLillyandCo is testing the first oral Lp(a) pill. No needle. Daily dose. 86% reduction in Phase 2.
-> And behind that: gene editing. One infusion. Potentially permanent.
-> @CRISPRTX cut Lp(a) by 73% in humans with a single dose (CTX320, Phase 1).
-> @editasmed just showed ~90% reduction in primates by editing LDLR regulatory regions instead of the Lp(a) gene itself.
-> @EliLillyandCo is developing its own one-time gene edit through Verve.
1 in 5 people carry elevated Lp(a). It’s over 90% genetic. Diet and exercise don’t touch it. 0.1% of Americans have ever been tested (Cleveland Clinic, 71 million records).
One blood draw. $25. Once in your life.
Five cancers that used to be death sentences. Pancreatic. Glioblastoma. Triple-negative breast. Renal. Melanoma. The median survival for metastatic pancreatic cancer is still 6 months. Glioblastoma, 15 months.
Now personalized mRNA vaccines are producing complete remissions in some of these patients. Not responses. Remissions.
BioNTech’s pancreatic cancer vaccine has 6-year follow-up data. 8 of 16 patients who mounted an immune response are still alive. For a cancer that kills 95% of patients within 5 years, that's incredible.
Topol’s pyramid here maps the trajectory. From broad checkpoint inhibitors at the base to personalized neoantigen vaccines at the peak. The technology is climbing.